

Tdap-IPV

Tetanus-Diphtheria-Acellular Pertussis-Polio Combined Vaccine

Revision Date: May 6, 2024

Rationale for Update:

- References to dTap changed to Tdap to align with national standards.

Please consult the Product Monograph ^(1,2) for further information about the vaccine.		
	ADACEL®-POLIO	BOOSTRIX®-POLIO
Manufacturer	Sanofi Pasteur Limited	GlaxoSmithKline Inc.
Licensed use	Booster immunization for individuals four years of age and older. ^(1,2)	
Off-license use	Primary immunization for individuals seven years and older who need diphtheria, tetanus, acellular pertussis and polio vaccines. ⁽³⁾	
Indications for use of provincially funded vaccine	<p>Children 4 years up to including 6 years of age:</p> <ul style="list-style-type: none">Reinforcing dose of diphtheria, tetanus, acellular pertussis and polio (preschool booster) – routine immunization program. <p>Individuals 7 years of age and older:</p> <ul style="list-style-type: none">Those initiating a primary vaccine series (unknown/uncertain or no history of a primary series) or completing a vaccine series (diphtheria, tetanus, acellular pertussis and polio).⁽³⁾Those who sustain a wound injury and have not received the age-appropriate number of tetanus and polio vaccine dose See Tetanus Post-exposure Prophylaxis in Injury/Wound Management. <p>Note:</p> <ul style="list-style-type: none">Individuals who have received hematopoietic stem cell transplantation: please see Immunization for Child Hematopoietic Stem Cell Transplant Recipients. and Immunization for Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients. <p>Notes:</p> <ul style="list-style-type: none">For those requiring polio only – see Biological Products Polio vaccine.For adult recipients of Hematopoietic Stem Cell Transplant (HSCT) and Solid Organ Transplant (SOT), see:<ul style="list-style-type: none">Adult HSCT andAdult SOT	
Dose	0.5mL	

Tdap-IPV Vaccine

Route	Intramuscular injection
Schedule	<p>Series:</p> <p>Individuals 7 years of age and older:⁽³⁾</p> <ul style="list-style-type: none"> ❖ Dose 1: day 0 ❖ Dose 2: 4 – 8 weeks after dose 1 ❖ Dose 3: 6 – 12 months after dose 2 <p>Reinforcing dose:</p> <ul style="list-style-type: none"> ❖ Children four years of age and older, at least 6 months from a previous dose of tetanus, diphtheria, acellular pertussis and polio containing vaccine. ❖ Other individuals when a dose of diphtheria, tetanus, acellular pertussis and polio vaccine is indicated.
Contraindications	<ul style="list-style-type: none"> • Known severe hypersensitivity to any component of the vaccine.^(1,2) • Anaphylactic or other allergic reaction to a previous dose of vaccine containing tetanus, diphtheria, pertussis or polio.^(1,2) • Encephalopathy (e. g., coma, decreased level of consciousness, prolonged seizures) within seven days of a previous dose of a pertussis-containing vaccine not attributable to another identifiable cause is a contraindication to immunization with any pertussis-containing vaccine.^(1,2,4)
Precautions	<ul style="list-style-type: none"> • Frequent booster doses of tetanus and diphtheria toxoids may lead to severe local and systemic reactions and may be associated with high levels of circulating antitoxin.⁽³⁾
Pregnancy	<ul style="list-style-type: none"> • Data from post-marketing surveillance where pregnant women were exposed to Tdap-IPV in third trimester do not suggest vaccine related adverse effect on pregnancy or on the health of the fetus/newborn child.^(1,2) • If Tdap-IPV is administered to a pregnant woman, it should ideally be done during the third trimester of pregnancy.^(1,2) • Human data from prospective clinical studies on the use of Tdap-IPV during the first and second trimester of pregnancy are not available.^(1,2) • However, inactivated vaccines and toxoids are generally considered safe in pregnancy.⁽²⁾
Lactation	May be administered to breastfeeding women if indicated. ^(1,2)
Program Notes	<ul style="list-style-type: none"> • 2012 September – Introduced into program for routine booster for 4-6 year olds replacing DTaP-IPV. • 2022 April 20 - Due to the limited supply of IPV vaccine, dTap-IPV is the vaccine of choice for adults who require polio immunization only. • 2024 January 29 - Removed limited supply constraints related to IPV vaccine. Adults in Health Care Settings should receive a primary series and a single lifetime reinforcing dose of polio-containing vaccine. Adults previously unimmunized with polio vaccine should receive a primary series. • 2024 May 6 - References to dTap changed to Tdap to align with national standards.

Tdap-IPV Vaccine

References

1. GlaxoSmithKline Inc. BOOSTRIX-POLIO (Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis) vaccine [Internet]. Product Monograph. 2023. p. 1–26. Available from: https://pdf.hres.ca/dpd_pm/00073318.PDF
2. Sanofi Pasteur Limited. Adacel®-polio Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine [Internet]. Product Monograph. 2023. p. 1–35. Available from: https://pdf.hres.ca/dpd_pm/00071963.PDF
3. National Advisory Committee on Immunization. Canadian Immunization Guide (Evergreen ed.) [Internet]. Ottawa, ON: Public Health Agency of Canada. Available from: www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php
4. Advisory Committee on Immunization Practices (ACIP). General best practice guidelines for immunization. [Internet]. 2023. Available from: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>